Robert J Decker Net Worth
Track Major Insider Updates On X/TwitterLast Updated: 3 days, 8 hours ago
Robert J Decker has an estimated net worth of at least $14.1 million*, as of March 11, 2026. They own 23,682 shares of JNJ stock. They have sold 47,099 shares of JNJ stock since 2021, for an estimated $8.4 million.
Robert J Decker $JNJ SEC Form 4 Insider Trading
Robert J Decker has filed a total of 6 insider trades in $JNJ since 2021. Their most recent trade was a sale of 4,075 shares, made on Feb 27, 2026. Their largest trade was a sale of 16,928 shares, made on Nov 18, 2022. We estimate that they now own 23,682 shares of $JNJ, worth an estimated $5.7 million.
Insider Trading at $JNJ
There have been a total of 373 insider trades reported at $JNJ since 2021, with 2,250 shares purchased and 1.2 million shares sold. The most active insider traders in $JNJ stock have been Peter Fasolo, Thibaut Mongon, and William Hait. The most recent trade was a sale of 4,075 shares reported by Robert J Decker (VP Corporate Controller), made on Feb 27, 2026.
History of Insider Stock Trades by Robert J Decker
| Company Ticker | Purchase / Sale | Shares | Date | Disclosed (EST) |
|---|---|---|---|---|
JNJ
|
Sale | 4,075 | Feb 27, 2026 | March 3, 2026, 5:21 p.m. |
|
JNJ
|
Sale | 6,999 | Feb 25, 2025 | Feb. 26, 2025, 7:42 p.m. |
|
JNJ
|
Sale | 5,635 | Aug 30, 2024 | Sept. 3, 2024, 4:48 p.m. |
|
JNJ
|
Sale | 16,928 | Nov 18, 2022 | Nov. 21, 2022, 5:33 p.m. |
|
JNJ
|
Sale | 8,462 | May 26, 2022 | May 31, 2022, 5:21 p.m. |
|
JNJ
|
Sale | 5,000 | Dec 07, 2021 | Dec. 9, 2021, 5:43 p.m. |
$JNJ Executives and Stock Owners with Insider Trades
-
Peter Fasolo, Exec VP, Chief HR Officer
-
Thibaut Mongon, Exec VP, WW Chair, Consumer
-
William Hait, See Remarks
-
Joseph J Wolk, Exec VP, CFO
-
John C Reed, EVP, Innovative Medicine, R&D
-
Kathryn E Wengel, EVP, Chief GSC Officer
-
Timothy Schmid, EVP, WW Chair, MedTech
-
Joaquin Duato, CEO and Chairman of the Board
-
Robert J Decker, Controller, CAO
-
Robert J Decker, VP Corporate Controller
-
James D. Swanson, EVP, CIO
-
Jennifer L Taubert, EVP, WW Chair, Pharmaceuticals
-
Vanessa Broadhurst, EVP, Global Corp Affairs
-
Ashley Mcevoy, EVP, WW Chair, MedTech
-
Jennifer L Taubert, EVP, WWC. Innovative Medicine
-
Kathryn E Wengel, EVP, Chief TO and Risk Officer
-
James D. Swanson, See Remarks
*This is only based off of information found in SEC filings, and may not reflect actual net worth. There may also be inaccuracies due to privately holdings filing errors, parsing errors, accidental double-counting of shares, incorrect classification of indirectly owned shares, sales prior to dataset start date, or any other number of issues.